AngioDynamics, Inc.

NasdaqGS:ANGO Stock Report

Market Cap: US$522.4m

AngioDynamics Management

Management criteria checks 2/4

AngioDynamics' CEO is Jim Clemmer, appointed in Apr 2016, has a tenure of 9.75 years. total yearly compensation is $5.49M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 1.31% of the company’s shares, worth $6.84M. The average tenure of the management team and the board of directors is 6.3 years and 9.9 years respectively.

Key information

Jim Clemmer

Chief executive officer

US$5.5m

Total compensation

CEO salary percentage14.62%
CEO tenure9.8yrs
CEO ownership1.3%
Management average tenure6.3yrs
Board average tenure9.9yrs

Recent management updates

Recent updates

The Market Doesn't Like What It Sees From AngioDynamics, Inc.'s (NASDAQ:ANGO) Revenues Yet

Dec 05
The Market Doesn't Like What It Sees From AngioDynamics, Inc.'s (NASDAQ:ANGO) Revenues Yet

We Think AngioDynamics (NASDAQ:ANGO) Can Afford To Drive Business Growth

Oct 03
We Think AngioDynamics (NASDAQ:ANGO) Can Afford To Drive Business Growth

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

Oct 02

Revenues Working Against AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price

Aug 26
Revenues Working Against AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price
User avatar

FDA Approval And International Expansion Will Redefine Healthcare Delivery

Growth in proprietary therapies and expanding adoption of key platforms are driving improved margins, higher recurring revenues, and long-term earnings visibility.

AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price Boosted 38% But Its Business Prospects Need A Lift Too

Jan 30
AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price Boosted 38% But Its Business Prospects Need A Lift Too

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

Jan 16

AngioDynamics: A Surgical Approach To Market Growth

Jan 08

There Is A Reason AngioDynamics, Inc.'s (NASDAQ:ANGO) Price Is Undemanding

Dec 10
There Is A Reason AngioDynamics, Inc.'s (NASDAQ:ANGO) Price Is Undemanding

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Jul 19
AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

Jul 18
Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

AngioDynamics: A Story To Monitor

May 14

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 09

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Apr 06
AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

AngioDynamics: Restructuring Initiative May Not Go Far Enough

Jan 14

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Oct 12
AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Mar 31
AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

CEO Compensation Analysis

How has Jim Clemmer's remuneration changed compared to AngioDynamics's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2025n/an/a

-US$32m

May 31 2025US$5mUS$803k

-US$34m

Feb 28 2025n/an/a

-US$41m

Nov 30 2024n/an/a

-US$225m

Aug 31 2024n/an/a

-US$243m

May 31 2024US$5mUS$783k

-US$184m

Feb 29 2024n/an/a

-US$192m

Nov 30 2023n/an/a

-US$14m

Aug 31 2023n/an/a

US$6m

May 31 2023US$4mUS$756k

-US$52m

Feb 28 2023n/an/a

-US$37m

Nov 30 2022n/an/a

-US$33m

Aug 31 2022n/an/a

-US$33m

May 31 2022US$6mUS$736k

-US$27m

Feb 28 2022n/an/a

-US$40m

Nov 30 2021n/an/a

-US$38m

Aug 31 2021n/an/a

-US$34m

May 31 2021US$4mUS$720k

-US$32m

Feb 28 2021n/an/a

-US$169m

Nov 30 2020n/an/a

-US$171m

Aug 31 2020n/an/a

-US$170m

May 31 2020US$3mUS$716k

-US$167m

Feb 29 2020n/an/a

-US$7m

Nov 30 2019n/an/a

-US$6m

Aug 31 2019n/an/a

-US$7m

May 31 2019US$3mUS$687k

-US$11m

Compensation vs Market: Jim's total compensation ($USD5.49M) is above average for companies of similar size in the US market ($USD2.33M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Clemmer (61 yo)

9.8yrs
Tenure
US$5,494,285
Compensation

Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Interim President of...

Leadership Team

NamePositionTenureCompensationOwnership
James Clemmer
CEO, President & Director9.8yrsUS$5.49m1.31%
$ 6.8m
Stephen Trowbridge
Executive VP & CFO6.3yrsUS$2.16m0.30%
$ 1.6m
Lawrence Weiss
Senior VP1.1yrsUS$1.46m0.024%
$ 126.8k
Warren Nighan
Senior Vice President of Regulatory Affairs8.8yrsUS$1.17m0.088%
$ 457.9k
Laura Piccinini
Senior VP and GM of Cardiovascular & International4.6yrsUS$1.37m0.036%
$ 185.7k
Saleem Cheeks
Vice President of Communications5.9yrsno datano data
Benjamin Davis
Senior Vice President of Business Development & Strategy10.8yrsno datano data
Marna Bronfen-Moore
Senior Vice President of Human Resources6.3yrsno datano data
Chad Campbell
Senior VP and GM of Oncology & Interventional Devices9.7yrsUS$1.01m0%
$ 0
Kim Seabury
Senior Vice President of Information Technology14.3yrsno datano data
Juan Serna
Senior Vice President of Scientific & Clinical Affairs5yrsno datano data
Jake Brumbaugh
Global Vice President for Marketing-Oncologyno datano datano data
6.3yrs
Average Tenure
56yo
Average Age

Experienced Management: ANGO's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Clemmer
CEO, President & Director9.8yrsUS$5.49m1.31%
$ 6.8m
Jan Reed
Independent Director9.2yrsUS$241.03k0.25%
$ 1.3m
Wesley Johnson
Independent Director19yrsUS$246.03k0.33%
$ 1.7m
Howard Donnelly
Independent Non-Executive Chairman21.8yrsUS$268.53k0.41%
$ 2.1m
Eileen Auen
Independent Director10yrsUS$238.53k0.25%
$ 1.3m
Michael Dake
Member of the Scientific Advisory Boardno datano datano data
Frank Veith
Member of the Scientific Advisory Boardno datano datano data
Thomas Sos
Member of the Scientific Advisory Boardno datano datano data
Stephen Kee
Member of the Scientific Advisory Boardno datano datano data
John Kaufman
Member of the Scientific Advisory Boardno datano datano data
Jacob Cynamon
Member of the Scientific Advisory Boardno datano datano data
Karen Licitra
Independent Director6.5yrsUS$231.03k0.22%
$ 1.1m
9.9yrs
Average Tenure
64.5yo
Average Age

Experienced Board: ANGO's board of directors are considered experienced (9.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/04 16:46
End of Day Share Price 2026/01/02 00:00
Earnings2025/08/31
Annual Earnings2025/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AngioDynamics, Inc. is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew TaylorBarclays
John YoungCanaccord Genuity
William PlovanicCanaccord Genuity